- Home
- WAVE vs NRXP Comparison
WAVE vs NRXP Comparison
Compare WAVE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- NRXP
- Stock Information
- Founded
- WAVE 2011
- NRXP 2015
- Country
- WAVE Israel
- NRXP United States
- Employees
- WAVE N/A
- NRXP N/A
- Industry
- WAVE Electric Utilities: Central
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- WAVE Utilities
- NRXP Health Care
- Exchange
- WAVE Nasdaq
- NRXP Nasdaq
- Market Cap
- WAVE 27.0M
- NRXP 32.6M
- IPO Year
- WAVE 2021
- NRXP N/A
- Fundamental
- Price
- WAVE $6.94
- NRXP $3.05
- Analyst Decision
- WAVE Strong Buy
- NRXP Strong Buy
- Analyst Count
- WAVE 1
- NRXP 4
- Target Price
- WAVE $15.00
- NRXP $28.50
- AVG Volume (30 Days)
- WAVE 18.8K
- NRXP 188.0K
- Earning Date
- WAVE 08-28-2025
- NRXP 08-13-2025
- Dividend Yield
- WAVE N/A
- NRXP N/A
- EPS Growth
- WAVE N/A
- NRXP N/A
- EPS
- WAVE N/A
- NRXP N/A
- Revenue
- WAVE $168,000.00
- NRXP N/A
- Revenue This Year
- WAVE $325.00
- NRXP N/A
- Revenue Next Year
- WAVE $85.71
- NRXP N/A
- P/E Ratio
- WAVE N/A
- NRXP N/A
- Revenue Growth
- WAVE N/A
- NRXP N/A
- 52 Week Low
- WAVE $2.39
- NRXP $1.10
- 52 Week High
- WAVE $17.63
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- WAVE 59.41
- NRXP 43.40
- Support Level
- WAVE $6.02
- NRXP $3.12
- Resistance Level
- WAVE $6.79
- NRXP $3.53
- Average True Range (ATR)
- WAVE 0.38
- NRXP 0.16
- MACD
- WAVE 0.04
- NRXP -0.07
- Stochastic Oscillator
- WAVE 88.03
- NRXP 3.92
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.